10161772To assess the feasibility of a digital platform for pregnancy sicknessActiveFeasibility StudiesInnovate UKMost people will have heard of the terms "morning sickness", however this term is misleading as the symptoms of Nausea and/or Vomiting (NVP) that are associated with the first trimester can occur at any time of the day, sometimes lasting all day. NVP affects up to 90% of pregnancies and exists on a spectrum. For some women these symptoms may be mild and manageable however for approximately two-thirds the symptoms are moderate to severe, impacting their everyday lives along with mental and physical wellbeing. Hyperemesis Gravidarum (HG) is at the severe end of this spectrum and is characterised by persistent and severe nausea and/or vomiting that disrupts a woman's ability to eat and drink normally, potentially leading to dehydration, weight loss, and even hospital admission. Despite its prevalence, NVP is often dismissed as a normal part of pregnancy which leads to inadequate support and care. Research shows that timely, evidence-based care can prevent deterioration of symptoms and complications. The aim of this project is to assess the feasibility of a healthcare platform that provides timely evidence based-support. Our comprehensive solution uses personalised medical intervention to help improve health outcomes as well as reducing healthcare system burden. The project will be grounded in rigorous user-engagement; throughout the study, we will work together with women who have first-hand experience of nausea and vomiting in pregnancy, alongside practising clinicians, to shape every stage of development. Our primary goal is to generate early evidence on two fronts: technical feasibility and user acceptability. By comparing real-world feedback with predefined success criteria, we will be able to judge whether this approach offers the most effective solution to the problem or whether refinements, alternate features or entirely different models are warranted. The findings will give us a clear, data-driven view of the platform's strengths and limitations, guiding decisions about wider implementation and further clinical evaluation.